34 results about "Nephrologic disease" patented technology

An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I).The compound represented by the formula (I) inhibits the increase of the intracellular calcium concentration, and therefore it is deemed to be useful as an agent for the prophylaxis and / or treatment of platelet aggregation, ischemic diseases in hearts and brains, immune deficiency diseases, allorgosis, bronchial asthma, hypertension, cerebrovascular spasm, various renal diseases, pancreatitis, Alzheimer's disease, etc.

Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit.

This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder. This invention provides compounds of oleanene triterpenoidal saponin in nature with the characteristics that at least one angeloyl group attached to Carbon 21 or / and 22, or / and linked to the sugar. The compounds of the present invention have various pharmaceutical and therapeutic applications.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

Inhibitors of mammalian protein kinase C isoforms that comprise an inhibitor moiety, which is capable of inhibiting protein kinase activity, operatively associated with a peptide recognition element (PRE), which has an affinity for one or more PKC isoforms are provided. The targeted inhibitory molecules (TIMs) of the present invention are capable of inhibiting one or more PKC isoforms. The TIMs can be designed to target a specific PKC isoform by selection of a PRE component that is shown to preferentially target that PKC isoform. The TIMs are useful as therapeutic agents in the treatment of PKC-related diseases and disorders, such as cancer, psoriasis, angiogenesis, restenosis, atherosclerosis, cardiovascular disease, hypertension, diabetes, neurological disorders, rheumatoid arthritis, kidney disorders, inflammatory disorders and autoimmune disorders.

Disclosed are a compound of formula (I) or pharmaceutically acceptable salt thereof, wherein R1 is selected from H, halogen, C1-2 alkyl, substituted C1-2 alkyl, and C1-2 alkoxy, and R1 is CH3 when ring A is pentabasic monocyclic heteroaryl; R2 is CN, I, C1, Br, -CF3, or -OCH3; R3 is H or D; ring A is thiazole, selenazole, oxazole, or pyridine; ring E is formula (A), (B), or (C); G1 is selected from O or NRa; G2, G3, and G4 are independently selected from -CRa or -CRbRc; Ra is selected from H, deuterium, halogen, C1-6 alkyl, or substituted C1-6 alkyl, and Ra does not comprise deuterium or halogen when Ra is connected to N; Rb and Rc are each independently selected from H, deuterium, halogen, C1-4 alkyl, or substituted C1-4 alkyl; and optionally Rb and Rc may cyclize to form C3-7 membered cycloalkyl or substituted C3-7 membered cycloalkyl. The compound or pharmaceutically acceptable salt thereof is used to prepare drugs for preventing or treating hyperuricemia, gout, diabetic nephropathy, inflammatory diseases, and neurological diseases.

A compound of the Formula (I) is disclosed: (I) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.

Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.

Methods and compositions for modulating cyclophilin D, e.g., at least one cyclophilin D biological activity, are provided. Modulation of cyclophilin D is useful in preventing or treating obesity, an overweight condition, or in accommodating a desire to lose weight as well as being useful in treating a variety of kidney diseases.

The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.

The present invention provides an isolated nucleic acid molecule encoding a brain cyclic nucleotide gated ion channel (BCNG) protein. An isolated BCNG protein is also provided as is a composition comprising a BCNG encoding nucleic acid or protein or a portion thereof. The present invention also provides a method of identifying an ion channel subunit related protein encoding nucleic acid molecule in a sample. The invention further provides a method for evaluating the ability of a compound to modulate an ion channel associated neurological, cardia, or renal condition. The invention also provides a method for evaluating the ability of a compound to interact with a BCNG-related ion channel subunit protein. Additionally, the present invention provides a method for identifying a compound capable of modulating the activity of a BCNG-related protein. The present invention additionally provides a method of treating a cardiac, renal or neurological condition. Finally, the present invention provides an antibody which specifically reacts with BCNG protein.

The present invention provides a prophylactic or therapeutic agent for a kidney disease, comprising AIM or a partial peptide thereof, or a nucleic acid comprising a base sequence encoding the same, or a screening method for a prophylactic or therapeutic agent for a kidney disease, comprising using an animal obtained by subjecting a non-human mammal deficient in AIM expression to unilateral ureteral obstruction or transient kidney ischemia / reperfusion and the like.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combinationwith at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

The present invention provides novel piperidinyl-containing nociceptin receptor ligand compounds and pharmaceutical compositions useful in the treatment of neurological diseases and conditions where such ligands mediate the negative effects of the condition. Such neurological diseases and conditions include acute and chronic pain, substance abuse / dependence, alcohol addiction, anxiety, depression,sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular disorders and Parkinson's disease.

The present invention includes pharmaceutical composition comprising (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide)(diNACA) or D3-N-acetyl cysteine amide, or a physiologically acceptable salt thereof, having a deuterium enrichment above the natural abundance of deuterium, and derivatives or solids thereof, and methods of using diNACA to treat eye diseases and other diseases associated with oxidative damage including, e.g., antivenom, beta-thallassemia, cataract, chronic obstructive pulmonary disease, macular degeneration, contrast-induced nephropathy, asthma, lung contusion, methamphetamine-induced oxidative stress, multiple sclerosis, Parkinson's disease, platelet apoptosis, Tardive dyskinesia, Alzheimer disease, HIV-1-associated dementia, mitochondrial diseases, myocardial myopathy, neurodegenerative diseases, pulmonary fibrosis, skin pigmentation, skin in need of rejuventation, antimicrobial infection, Friedreich's ataxia.

Compositions and methods are disclosed herein for treating or reducing the symptoms of a renal disease, such as focal segmental glomerulosclerosis (FSGS), hypertensive end-stage kidney disease (ESKD), and HIV-associated nephropathy (a distinct form of FSGS, also termed collapsing glomerulopathy). The compositions include the common variant of APOL1 and fragments thereof, as well as antibodies and fragments thereof that bind and neutralize pathogenic APOL1, nucleic acid molecules that encode the common variant of APOL1 and fragments thereof, and other compounds that bind and neutralize pathogenic APOL1. The methods of the invention include administering one or more of the compositions of the invention to a subject having or at risk of developing renal disease.

The claimed invention addresses the benefits of exogenous ketone supplementation in a subject in need thereof. In particular, the exogenous ketone supplementation includes the natural D-Beta HydroxyButyric acid, also described as natural D-BHB. As detailed in representative FIG. 1, natural D-BHB is preferentially consumed in the brain to glucose and additionally has a wide range of positive regulatory effects on the body and mind. Consumer applications for supplementation with natural D-BHB include improved sleep, anti-hunger, anti-anxiety, improved cognitive enhancement and athletic duration and post workout recovery through consumption of 10 grams or more of natural D-BHB. Therapeutic applications for exogenous natural D-BHB supplementation include anti-cancer, anti-kidney disease, anti-cognitive disorders and improved viral resistance through consumption of 10-20 grams or more of D-Beta HydroxyButyric acid.

The invention relates to a pharmaceutical application of (E)-3-aromatic heterocyclic propyl-2-olefine acid derivatives. The compound is a novel Nrf2 activator, and has the effects of resisting oxidative stress, resisting neuritis and enhancing mitochondrial function and biogenesis by effectively activating an Nrf2 signal channel, so that nerve cells are protected, and the compound can be used for treating neurodegenerative diseases and cerebral apoplexy. In addition, such novel Nrf2 activators can also be used for the treatment of autoimmune diseases, diabetes and nephropathy as well as other chronic diseases.

The invention discloses a traditional Chinese medicine composition for treating yin-deficiency and interior-heat IgA nephropathy. The IgA nephropathy belongs to the domains of hematuresis, edema, anemogenous nephropathy, consumptive disease and the like in motherland medicine, and is caused by spleen-qi deficiency, failure of keeping fluid due to qi deficiency, and lifting dysfunction. The pathogenesis is heat, blood stasis and deficiency. The traditional Chinese medicines with the effects of promoting blood circulation to remove blood stasis, tonifying the spleen and reinforcing the kidneys, supplementing qi and nourishing yin, and clearing heat and cooling blood, such as fine-stemmed dendrobium, dunn antiotrema root, adiantum soboliferum, ricepaperplant root, oriental waterplantain fruit, thinleaf adina fruit, herba ecliptae and phoenix hawksbeard root are selected to be decocted into decoction. The total effective rate of a treatment group is 96%, and obviously superior to that of a control group, and no bad reaction is generated by a clinical test.

Provided is a kampo medicine for treating multimorbidity of Alzheimer-type dementia or mild cognitive impairment and at least one disease from the group consisting of overactive bladder, constipation, and chronic kidney disease with one drug. A kampo medicine for treating multimorbidity with one drug, comprising a drug combination of orengedokuto and ryokeijutsukanto as an active ingredient, wherein the kampo medicine improves a cognitive function in Alzheimer-type dementia or mild cognitive impairment and relieves and treats at least one disease from overactive bladder, constipation, and chronic kidney disease complicated by Alzheimer-type dementia or mild cognitive impairment at a high rate with one drug.

Featured are methods and compositions for treating, managing, preventing, or reducing injury to the kidney of a mammal (e.g., a human) caused by one or more iodinated radiocontrast media. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP / VIP receptors, including all of their various isoforms. Also provided are pharmaceutical compositions of one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic / therapeutic agents useful for treating, managing, or preventing injury to the kidney of a mammal (e.g., a human) undergoing treatment with one or more iodinated radiocontrast media. Also featured is an in vivo mouse model for testing the efficacy of cytoprotective agents against contrast-induced nephropathy.

The invention is concerned with use of oral inorganic pyrophosphate for preventing and / or reducing tissue calcification, particularly soft tissue calcification, and / or diseases or disorders characterized by low plasma PPi levels, as, e.g., occurs in chronic kidney disease (CKD), end-stage renal disease (ESRD), generalized arterial calcification of infancy (GACI), Pseudoxanthoma elasticum (PXE), Arterial Calcification Due to Deficiency of CD73 (ACDC), Ehlers-Danlos syndrome, arteriosclerosis obliterans, venous calcifications, crystal deposition disorders, calcification resulting from neurological disorders, calcinosis universalis, calcinosis circumscripta, scleroderma, dermatomyositis, systemic lupus erythematosus, hyperparathyroidism, neoplasms, milk-alkali syndrome, hypervitaminosis D, tumoral calcinosis, hypophosphatemic rickets, ossification of the posterior longitudinal ligament of the spine, myocardial ischemia, joint calcification, heterotropic ossification of traumatized muscle, angioid streaks, diabetes mellitus type II, cardiovascular disorder, or atherosclerosis.

The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I:wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein.The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases / injuries associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson's disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Sträussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III and methods for the treatment of cardiovascular and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, postprandial hyperglycemia, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, inflammation, Crohn's disease, inflammatory bowel disease and obesity.

The invention discloses a biscuit suitable for nephropathy patients to eat. The biscuit is characterized by being prepared from the following raw materials in parts by weight: 20-30 parts of lotus root starch, 3-7 parts of isomaltooligosacharide, 2-5 parts of yeast glucan, 2-4 parts of corn oil, 1-5 parts of agarose, 10-15 parts of inulin, 5-10 parts of mono-6-amino-6-deoxy-beta-cyclodextrin gluconate, 1-3 parts of a Chinese herbal medicine extract, 1-3 parts of baking powder and 15-20 parts of water. The biscuit suitable for nephropathy patients to eat can effectively improve nutritional deficiency and delay the process of deterioration of renal function. The biscuit has balanced nutrition, good absorption effect and good taste, can effectively improve the intestinal functions, removes the toxins produced by intestinal microorganisms, and meets the nutritional requirements of low protein intake of nephropathy patients.

The present invention relates to antibodies specifically reacting with partial peptides in the C-terminal region of polypeptides having amino acid sequences represented by SEQ ID NOS: 1 through 8 or derivatives thereof, a method of quantifying urotensin II using the antibodies, and pharmaceutical compositions comprising the antibodies (e.g., for central nerve diseases, mental disorders, circulatory diseases, heart diseases, renal diseases, urinary tract disorders, or the like).

The invention relates to a (E)-3-heteroaromatic propyl-2-enoic acid derivative, and also relates to a preparation method and pharmaceutical application thereof. The compound is a novel Nrf2 activatorand has the effects of resisting oxidative stress, resisting neuritis and enhancing mitochondrial functions and biogenesis by effectively activating an Nrf2 signal path, so that nerve cells are protected, and the compound can be used for treating neurodegenerative diseases and cerebral apoplexy. In addition, the novel Nrf2 activator can also be used to treat autoimmune diseases, diabetes and nephropathy, and other chronic diseases.

The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.

The present invention is directed to amino and alkyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.